Glaukos Corporation (GKOS) Reports 2-Yr U.S. IDE Pivotal Trial Results for iStent Inject Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery
Tweet Send to a Friend
Glaukos Corporation (NYSE: GKOS) today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE